Placebo effect of medication cost in Parkinson disease: a randomized double-blind study.

Academic Article

Abstract

  • OBJECTIVE: To examine the effect of cost, a traditionally "inactive" trait of intervention, as contributor to the response to therapeutic interventions. METHODS: We conducted a prospective double-blind study in 12 patients with moderate to severe Parkinson disease and motor fluctuations (mean age 62.4 ± 7.9 years; mean disease duration 11 ± 6 years) who were randomized to a "cheap" or "expensive" subcutaneous "novel injectable dopamine agonist" placebo (normal saline). Patients were crossed over to the alternate arm approximately 4 hours later. Blinded motor assessments in the "practically defined off" state, before and after each intervention, included the Unified Parkinson's Disease Rating Scale motor subscale, the Purdue Pegboard Test, and a tapping task. Measurements of brain activity were performed using a feedback-based visual-motor associative learning functional MRI task. Order effect was examined using stratified analysis. RESULTS: Although both placebos improved motor function, benefit was greater when patients were randomized first to expensive placebo, with a magnitude halfway between that of cheap placebo and levodopa. Brain activation was greater upon first-given cheap but not upon first-given expensive placebo or by levodopa. Regardless of order of administration, only cheap placebo increased activation in the left lateral sensorimotor cortex and other regions. CONCLUSION: Expensive placebo significantly improved motor function and decreased brain activation in a direction and magnitude comparable to, albeit less than, levodopa. Perceptions of cost are capable of altering the placebo response in clinical studies. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that perception of cost is capable of influencing motor function and brain activation in Parkinson disease.
  • Published In

  • Neurology  Journal
  • Keywords

  • Aged, Antiparkinson Agents, Cost of Illness, Cross-Over Studies, Dopamine Agonists, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Levodopa, Male, Middle Aged, Parkinson Disease, Placebo Effect, Prospective Studies, Treatment Outcome
  • Digital Object Identifier (doi)

    Author List

  • Espay AJ; Norris MM; Eliassen JC; Dwivedi A; Smith MS; Banks C; Allendorfer JB; Lang AE; Fleck DE; Linke MJ
  • Start Page

  • 794
  • End Page

  • 802
  • Volume

  • 84
  • Issue

  • 8